Patient characteristics
| Characteristic . | Value . |
|---|---|
| Median age, y (range) | 65 (44-76) |
| Sex | |
| Female | 27 |
| Male | 34 |
| Presence of heavy chain | |
| Yes | 24 |
| No | 37 |
| Monoclonal light chain, no. of patients | |
| Kappa | 15 |
| Lambda | 46 |
| Median absolute involved free light chain concentration, mg/L (range)* | 237 (27-1840) |
| Kappa | 467 |
| Lambda | 202 |
| Plasma cell content of the bone marrow, median % (range) | 10 (1-90) |
| Number of organs involved, no. of patients | |
| 1 organ | 5 |
| 2 organs | 25 |
| 3 or more organs | 31 |
| Dominant organ, no. of patients | |
| Heart | 28 |
| Liver | 5 |
| Gut | 4 |
| Kidney | 21 |
| Peripheral nerves | 1 |
| Soft-tissue involvement | 2 |
| NYHA stage, no. of patients | |
| 0 | 4 |
| 1 | 2 |
| 2 | 14 |
| 3 | 36 |
| n.a. | 5 |
| NT-proBNP, ng/L, median (range)* | 4420 (157-27 624) |
| cTNT, μg/L, median (range)* | 0.04 (< 0.005-0.6) |
| Mayo stage, no. of patients* | |
| 1 | 5 |
| 2 | 20 |
| 3 | 28 |
| n.a. | 8 |
| Median Karnofsky Index (range) | 80% (50-90) |
| Median creatinine clearance, mL/min (range)* | 51 (17-134) |
| Median albumin in serum, g/L (range) | 35 (21-49) |
| Reason not eligible for ASCT, no. of patients | |
| Age | 17 |
| Patient refusal | 2 |
| NYHA stage > 2 | 33 |
| Performance status > 2 or Karnofsky Index < 80% | 6 |
| Severe factor X deficiency | 1 |
| Symptomatic pleural effusion | 2 |
| Characteristic . | Value . |
|---|---|
| Median age, y (range) | 65 (44-76) |
| Sex | |
| Female | 27 |
| Male | 34 |
| Presence of heavy chain | |
| Yes | 24 |
| No | 37 |
| Monoclonal light chain, no. of patients | |
| Kappa | 15 |
| Lambda | 46 |
| Median absolute involved free light chain concentration, mg/L (range)* | 237 (27-1840) |
| Kappa | 467 |
| Lambda | 202 |
| Plasma cell content of the bone marrow, median % (range) | 10 (1-90) |
| Number of organs involved, no. of patients | |
| 1 organ | 5 |
| 2 organs | 25 |
| 3 or more organs | 31 |
| Dominant organ, no. of patients | |
| Heart | 28 |
| Liver | 5 |
| Gut | 4 |
| Kidney | 21 |
| Peripheral nerves | 1 |
| Soft-tissue involvement | 2 |
| NYHA stage, no. of patients | |
| 0 | 4 |
| 1 | 2 |
| 2 | 14 |
| 3 | 36 |
| n.a. | 5 |
| NT-proBNP, ng/L, median (range)* | 4420 (157-27 624) |
| cTNT, μg/L, median (range)* | 0.04 (< 0.005-0.6) |
| Mayo stage, no. of patients* | |
| 1 | 5 |
| 2 | 20 |
| 3 | 28 |
| n.a. | 8 |
| Median Karnofsky Index (range) | 80% (50-90) |
| Median creatinine clearance, mL/min (range)* | 51 (17-134) |
| Median albumin in serum, g/L (range) | 35 (21-49) |
| Reason not eligible for ASCT, no. of patients | |
| Age | 17 |
| Patient refusal | 2 |
| NYHA stage > 2 | 33 |
| Performance status > 2 or Karnofsky Index < 80% | 6 |
| Severe factor X deficiency | 1 |
| Symptomatic pleural effusion | 2 |
ASCT indicates autologous stem cell transplantation; cTNT, cardiac troponin T; n.a., not applicable; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; and NYHA, New York Heart Association.
Patients on dialysis (n = 6) were excluded.